Mark A. Socinski, MD

Articles

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer

March 17th 2022

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

Clinical Management of NTRK+ Advanced NSCLC

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Clinical Management of RET+ Advanced NSCLC

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

RET Alterations in Advanced NSCLC

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ROS1+ Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

ROS1 Alterations in Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

Clinical Management of ALK+ Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

ALK Alterations in Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Testing for Gene Alterations and Protein Expression in Advanced NSCLC

October 11th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC

October 11th 2021

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.

Final Thoughts on Effective Therapy and Financial Toxicity

September 20th 2021

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

Innovation of Therapies vs Disruptive Pricing

September 20th 2021

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity

September 13th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.

Review of GEMSTONE-301 and -302 Data

September 13th 2021

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Pharmacoeconomic Considerations for Immunotherapy

September 7th 2021

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers

August 30th 2021

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Place for EGFR Agents and Comparison of Costs

August 30th 2021

A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.